Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson's.

Clinical outcome assessments Early-stage Parkinson’s Mobility Parkinson’s Patient expert Patient-reported outcome instrument Qualitative evidence Slowness

Journal

Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688

Informations de publication

Date de publication:
20 04 2023
Historique:
received: 31 10 2022
accepted: 15 03 2023
medline: 20 4 2023
pubmed: 20 4 2023
entrez: 20 04 2023
Statut: epublish

Résumé

Previous research on concepts that are important to people living with early-stage Parkinson's indicated that 'functional' slowness, fine motor skills, and subtle gait abnormalities are cardinal concepts that are not comprehensively captured by existing patient-reported outcome (PRO) instruments that are used in clinical practice and research to assess symptoms and daily functioning within this patient population. We sought to develop novel PRO instruments to address this unmet need. PRO instrument development was led by a multidisciplinary research group, including people living with Parkinson's (termed 'patient experts'), as well as patient engagement and involvement, regulatory science, clinical, and outcome measurement experts. A first set of PRO instruments, termed Early Parkinson's Function Slowness (42 items) and Early Parkinson's Mobility (26 items), were drafted to capture 'functional' slowness, fine motor skills, and subtle gait abnormalities. These PRO instruments were used in cognitive debriefing interviews with people living with early-stage Parkinson's (who were not involved with the multidisciplinary research group) to identify issues with relevance, clarity, ease of completion, conceptual overlap, or missing concepts. Sixty people living with early-stage Parkinson's were interviewed, which led to refining the items to 45 for the Early Parkinson's Functional Slowness and 23 for the Early Parkinson's Mobility PRO instruments. Refinement included rewording items to address clarity issues, merging or splitting items to address overlap issues, and adding new items to address missing concepts. The Early Parkinson's Function Slowness PRO instrument resulted in a multidimensional instrument covering upper limb, complex/whole body, general activity, and cognitive functional slowness. The Early Parkinson's Mobility PRO instrument resulted in comprehensive coverage of everyday mobility tasks, with a focus on gait concepts, plus complex/whole body, balance, and lower limb mobility. The Early Parkinson's Function Slowness and Early Parkinson's Mobility PRO instruments aim to address gaps in existing PRO instruments to measure meaningful symptoms and daily functioning in people living with early-stage Parkinson's. Utilizing a meticulous study design led by a multidisciplinary research group that included patient experts helped to ensure that the PRO instruments were patient-centric, content valid, and meaningful from a clinical and measurement perspective.

Sections du résumé

BACKGROUND
Previous research on concepts that are important to people living with early-stage Parkinson's indicated that 'functional' slowness, fine motor skills, and subtle gait abnormalities are cardinal concepts that are not comprehensively captured by existing patient-reported outcome (PRO) instruments that are used in clinical practice and research to assess symptoms and daily functioning within this patient population. We sought to develop novel PRO instruments to address this unmet need.
METHODS
PRO instrument development was led by a multidisciplinary research group, including people living with Parkinson's (termed 'patient experts'), as well as patient engagement and involvement, regulatory science, clinical, and outcome measurement experts. A first set of PRO instruments, termed Early Parkinson's Function Slowness (42 items) and Early Parkinson's Mobility (26 items), were drafted to capture 'functional' slowness, fine motor skills, and subtle gait abnormalities. These PRO instruments were used in cognitive debriefing interviews with people living with early-stage Parkinson's (who were not involved with the multidisciplinary research group) to identify issues with relevance, clarity, ease of completion, conceptual overlap, or missing concepts.
RESULTS
Sixty people living with early-stage Parkinson's were interviewed, which led to refining the items to 45 for the Early Parkinson's Functional Slowness and 23 for the Early Parkinson's Mobility PRO instruments. Refinement included rewording items to address clarity issues, merging or splitting items to address overlap issues, and adding new items to address missing concepts. The Early Parkinson's Function Slowness PRO instrument resulted in a multidimensional instrument covering upper limb, complex/whole body, general activity, and cognitive functional slowness. The Early Parkinson's Mobility PRO instrument resulted in comprehensive coverage of everyday mobility tasks, with a focus on gait concepts, plus complex/whole body, balance, and lower limb mobility.
CONCLUSIONS
The Early Parkinson's Function Slowness and Early Parkinson's Mobility PRO instruments aim to address gaps in existing PRO instruments to measure meaningful symptoms and daily functioning in people living with early-stage Parkinson's. Utilizing a meticulous study design led by a multidisciplinary research group that included patient experts helped to ensure that the PRO instruments were patient-centric, content valid, and meaningful from a clinical and measurement perspective.

Identifiants

pubmed: 37079119
doi: 10.1186/s41687-023-00577-9
pii: 10.1186/s41687-023-00577-9
pmc: PMC10119343
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

40

Informations de copyright

© 2023. The Author(s).

Références

JAMA Neurol. 2022 Sep 1;79(9):929-936
pubmed: 35816299
RMD Open. 2015 Aug 05;1(1):e000129
pubmed: 26509075
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S34-6
pubmed: 22166448
Expert Opin Pharmacother. 2011 Jun;12(8):1249-58
pubmed: 21345151
Mov Disord. 2021 Jan;36(1):59-63
pubmed: 33026697
N Engl J Med. 2022 Aug 4;387(5):421-432
pubmed: 35921451
Mov Disord. 2004 Sep;19(9):1020-8
pubmed: 15372591
Mov Disord. 2018 May;33(5):771-782
pubmed: 29572948
Qual Life Res. 2013 Sep;22(7):1543-53
pubmed: 23070750
Metabolism. 2015 Mar;64(3 Suppl 1):S40-6
pubmed: 25510818
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
J Parkinsons Dis. 2022;12(4):1073-1082
pubmed: 35527571
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Health Expect. 2020 Aug;23(4):722-730
pubmed: 32363785
N Engl J Med. 2022 Aug 4;387(5):408-420
pubmed: 35921450
J Parkinsons Dis. 2022;12(4):1345-1351
pubmed: 35466955
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
Rheumatology (Oxford). 2022 Aug 3;61(8):3329-3340
pubmed: 34897375
Neurol Ther. 2022 Sep;11(3):1319-1340
pubmed: 35778541
Arch Neurol. 2000 Mar;57(3):369-72
pubmed: 10714663
Brain. 2017 Feb;140(2):429-441
pubmed: 28082300
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184

Auteurs

Thomas Morel (T)

UCB Pharma, Allée de la Recherche 60, 1070, Anderlecht, Brussels, Belgium. Thomas.Morel@ucb.com.

Sophie Cleanthous (S)

Modus Outcomes, a Division of Thread, London, UK.

John Andrejack (J)

Parkinson's Foundation, New York, NY, USA.

Roger A Barker (RA)

University of Cambridge, Cambridge, UK.

Milton Biagioni (M)

UCB Pharma, Allée de la Recherche 60, 1070, Anderlecht, Brussels, Belgium.

Geraldine Blavat (G)

Parkinson's Foundation, New York, NY, USA.

Bastiaan R Bloem (BR)

Radboud University Medical Centre; Donders Institute for Brain, Cognition and Behaviour; Department of Neurology; Centre of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.

Babak Boroojerdi (B)

UCB Biosciences GmbH, Monheim, Germany.

William Brooks (W)

Parkinson's Foundation, New York, NY, USA.

Paul Burns (P)

Parkinson's UK, London, UK.

Stefan Cano (S)

Modus Outcomes, a Division of Thread, London, UK.

Casey Gallagher (C)

Parkinson's Foundation, New York, NY, USA.

Lesley Gosden (L)

Parkinson's UK, London, UK.

Carroll Siu (C)

Parkinson's UK, London, UK.

Ashley F Slagle (AF)

Aspen Consulting, LLC, Steamboat Springs, CO, USA.

Natasha Ratcliffe (N)

Parkinson's UK, London, UK.

Karlin Schroeder (K)

Parkinson's Foundation, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH